Immunoglobulin News and Research

RSS

Robust passive and active immunity found in infants born to COVID-19 positive mothers

A new study provides evidence that babies born to mothers who were COVID-19 positive two or more months before delivery are protected by maternal antibodies, besides mounting a robust immune response in case they contract the infection in the perinatal period.

5 May 2021

Pregnancy may increase the risk of COVID-19 severity

Against the background of the COVID-19 pandemic, the impact of SARS-CoV-2 infection in pregnancy has been a subject of much controversy. In order to help answer the question as to whether this infection causes significant harm in pregnancy, a new study, released as a medRxiv* preprint, reports on the disease outcomes of this infection in pregnant women.

5 May 2021

Monoclonal antibody neutralizes all SARS-CoV-2 variants of concern

Researchers in Canada and the United States have identified a monoclonal antibody that potently neutralizes variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent responsible for the ongoing coronavirus disease 2019 (COVIdD-19) pandemic.

3 May 2021

COVID-19 may not have appeared first in China, suggests new genomic study

A new study in Acta Mathematica Scientia suggests that the virus may have originated in multiple countries almost simultaneously, rather than spreading from China to the rest of the world.

3 May 2021

Recovered COVID-19 patients show signs of long-term immunity

A study conducted by researchers in the United States has found that most patients who recovered from coronavirus disease 2019 (COVID-19) showed signs of long-lasting immunity against the causative agent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

28 Apr 2021

Real-world study in India finds COVISHIELD vaccine safe and effective

New research led by Naresh Trehan of Medanta-The Medicity in India found the COVISHIELD (ChAdOx1 nCoV-19 Corona Virus Vaccine) vaccine produced an immune response from the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) two weeks after vaccination with limited side effects.

26 Apr 2021

Study focuses on SARS-CoV-2 antibody seroprevalence in Wuhan and COVID-19 controls

Since the emergence in December 2019 in Wuhan, China, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread worldwide via transmission among close human contacts. Early on, several public health interventions were implemented in Wuhan city and Hubei Province, including lockdowns, social distancing, traffic restrictions, stay-at-home policies, face mask requirements, building temporary hospitals, and centralized quarantine. There were 50,355 confirmed cases of SARS-CoV-2 infection in Wuhan as of 28 January 2021.

25 Apr 2021

Single dose of Pfizer-BioNTech COVID-19 vaccine induces immunity in CML patients

Researchers in the UK have shown that a single dose of the Pfizer-BioNTech vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) induced antibody and cellular responses in patients with chronic myeloid leukemia (CML) who were taking tyrosine kinase inhibitors.

25 Apr 2021

NIAID establishes a clinical research network to improve understanding of childhood asthma

The National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, has awarded $10 million in first-year funding to establish a clinical research network called Childhood Asthma in Urban Settings (CAUSE).

23 Apr 2021

SARS-CoV-2 vaccine with single-cycle adenovirus vector

Researchers in the United States have developed adenovirus vectors that may be more effective at generating immune responses against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) than those used in the vaccines that are currently being rolled out to help combat the coronavirus disease 2019 (COVID-19) pandemic.

21 Apr 2021

Can a single BNT162b2 vaccine dose confer protective immunity against SARS-CoV-2 variants?

A team of researchers in Germany aimed to determine if the Pfizer-BioNTech vaccine mRNA vaccine (also known as the BNT162b2 vaccine) induces robust antibody responses against emergent SARS-CoV-2 variants, including the United Kingdom (or B1.1.7) variant; the South African (or B.1.351) variant; and the Brazilian (or P.1) variant.

21 Apr 2021

Characterization of lab-produced neutralizing antibodies targeting SARS-CoV-2

A new study led by Hans-Martin Jäck of the Friedrich-Alexander University Erlangen-Nuremberg in Germany engineered clusters of neutralizing monoclonal antibodies using a transgenic mouse model. A unique characteristic for the antibodies was the different ways it bound to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the overall reduction in the viral spread for human ACE2.

21 Apr 2021

Seroprevalence studies monitoring SARS-CoV-2 among vaccinees require more than spike assays

Researchers in the United States have shown that an antibody test measuring host reactivity to the nucleocapsid protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may better detect natural infection among vaccinated individuals than an assay that measures reactivity to the viral spike protein.

21 Apr 2021

Can fingerprick blood tests help evaluate antibody response and longevity against SARS-CoV-2 post-vaccination?

To monitor antibody level duration of vaccine-induced immune responses, a team of researchers in the U.S. – at Diacarta, University of California and VA Healthcare System, and the Franciscan University of Steubenville – evaluated the feasibility of using a single drop of fingerstick blood collected with flocked swabs for quantitative antibody response evaluation after COVID-19 vaccination.

20 Apr 2021

One dose of mRNA vaccine may be sufficient for individuals previously infected with SARS-CoV-2

A recent scientific report from Israel shows how healthcare workers previously infected with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) present with higher Immunoglobulin G (IgG) titers after receiving one dose of Pfizer–BioNTech COVID-19 vaccine in comparison to their fully vaccinated, never-infected counterparts. Conversely, the occurrence of post-vaccination infection does not increase IgG titers.

19 Apr 2021

Novel mRNA delivery vehicle provides alternative to LNPs for SARS-CoV-2 vaccines

Researchers in the United States have developed an alternative messenger RNA (mRNA) delivery platform to the lipid nanoparticles that are currently used in vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19).

18 Apr 2021

COVID-19 vaccination of lactating mothers elicits specific IgA antibodies in breast milk

A new study, released on the medRxiv* preprint server, examines the presence of SARS-CoV-2-specific IgA in human milk and its association with the protection of breastfed infants against the disease.

16 Apr 2021

COVID-19 vaccine INO-4800 shows efficacy against SARS-CoV-2 variants

Researchers in the United States have demonstrated the efficacy of the vaccine INO-4800 against variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19).

15 Apr 2021

Evidence of sustained immune responses weeks after Pfizer-BioNTech BNT162b2 vaccination

A new study published ahead of print in the Clinical Chemistry and Laboratory Medicine (CCLM) journal reports the production of a robust immune response against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) using the Pfizer-BioNTech BNT162b2 vaccine. The increase in humoral immunity includes elevated Immunoglobulin G (IgG) and Immunoglobulin A (IgA) levels after the second mRNA dose.

14 Apr 2021

A new polymersome-based SARS-CoV-2 nanovaccine elicits robust immunity

As newer vaccines are being developed to combat the ongoing pandemic of coronavirus disease 2019 (COVID-19), targeting the pathogen, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a new preprint research paper posted to the bioRxiv server describes a new subunit nanovaccine that appears to have robust immunogenicity and neutralizing activity.

14 Apr 2021

Immunoglobulin News and Research

Robust passive and active immunity found in infants born to COVID-19 positive mothers

Pregnancy may increase the risk of COVID-19 severity

Monoclonal antibody neutralizes all SARS-CoV-2 variants of concern

COVID-19 may not have appeared first in China, suggests new genomic study

Recovered COVID-19 patients show signs of long-term immunity

Real-world study in India finds COVISHIELD vaccine safe and effective

Study focuses on SARS-CoV-2 antibody seroprevalence in Wuhan and COVID-19 controls

Single dose of Pfizer-BioNTech COVID-19 vaccine induces immunity in CML patients

NIAID establishes a clinical research network to improve understanding of childhood asthma

SARS-CoV-2 vaccine with single-cycle adenovirus vector

Can a single BNT162b2 vaccine dose confer protective immunity against SARS-CoV-2 variants?

Characterization of lab-produced neutralizing antibodies targeting SARS-CoV-2

Seroprevalence studies monitoring SARS-CoV-2 among vaccinees require more than spike assays

Can fingerprick blood tests help evaluate antibody response and longevity against SARS-CoV-2 post-vaccination?

One dose of mRNA vaccine may be sufficient for individuals previously infected with SARS-CoV-2

Novel mRNA delivery vehicle provides alternative to LNPs for SARS-CoV-2 vaccines

COVID-19 vaccination of lactating mothers elicits specific IgA antibodies in breast milk

COVID-19 vaccine INO-4800 shows efficacy against SARS-CoV-2 variants

Evidence of sustained immune responses weeks after Pfizer-BioNTech BNT162b2 vaccination

A new polymersome-based SARS-CoV-2 nanovaccine elicits robust immunity

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News